Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015

Primary prevention through the use of human papillomavirus (HPV) vaccination is expected to impact both cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS). While CIN is well described, less is known about the epidemiology of AIS, a rare cervical precancer. We identified AIS an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2020-02, Vol.146 (3), p.810-818
Hauptverfasser: Cleveland, Angela A., Gargano, Julia W., Park, Ina U., Griffin, Marie R., Niccolai, Linda M., Powell, Melissa, Bennett, Nancy M., Saadeh, Kayla, Pemmaraju, Manideepthi, Higgins, Kyle, Ehlers, Sara, Scahill, Mary, Johnson Jones, Michelle L., Querec, Troy, Markowitz, Lauri E., Unger, Elizabeth R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Primary prevention through the use of human papillomavirus (HPV) vaccination is expected to impact both cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS). While CIN is well described, less is known about the epidemiology of AIS, a rare cervical precancer. We identified AIS and CIN grade 3 (CIN3) cases through population‐based surveillance, and analyzed data on HPV types and incidence trends overall, and among women screened for cervical cancer. From 2008 to 2015, 470 AIS and 6,587 CIN3 cases were identified. The median age of women with AIS was older than those with CIN3 (35 vs. 31 years; p 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.32340